Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Fauci: Considerable Pharma Interest In Zika Vaccine

This article was originally published in Scrip

Executive Summary

Unlike what happened with the Ebola virus, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), said he doesn't foresee any trouble in getting biopharmaceutical partners on board to pursue a vaccine against the Zika virus, a mosquito-borne infection that has quickly spread throughout 22 countries in Central and South America and the Caribbean since this past May, when it was first detected in Brazil.


Related Content

Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract